Amgen says biosimilars represent an opportunity to get to market without the risk or cost of a novel biologic, so long as you have the capabilities. Within the biosimilar space, Amgen is curiously conflicted. It is one of the largest and most successful developers of such products, yet the firm is defending several of its novel blockbuster biologics from other biosimilar makers. In the US, where, Amgen has three approved products, launching two of them – Mvasi and Kanjiti, versions…